Marker Therapeutics, Inc. (MRKR)
NASDAQ: MRKR · Real-Time Price · USD
0.9230
+0.0310 (3.48%)
At close: Nov 14, 2025, 4:00 PM EST
0.9414
+0.0184 (1.99%)
After-hours: Nov 14, 2025, 7:02 PM EST
Marker Therapeutics Revenue
Marker Therapeutics had revenue of $1.23M in the quarter ending September 30, 2025, a decrease of -35.99%. This brings the company's revenue in the last twelve months to $4.69M, down -12.99% year-over-year. In the year 2024, Marker Therapeutics had annual revenue of $6.59M with 99.06% growth.
Revenue (ttm)
$4.69M
Revenue Growth
-12.99%
P/S Ratio
2.51
Revenue / Employee
$938,998
Employees
5
Market Cap
11.94M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6.59M | 3.28M | 99.06% |
| Dec 31, 2023 | 3.31M | -202.41K | -5.76% |
| Dec 31, 2022 | 3.51M | 2.27M | 182.96% |
| Dec 31, 2021 | 1.24M | 774.93K | 166.01% |
| Dec 31, 2020 | 466.79K | 253.59K | 118.95% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
MRKR News
- 2 days ago - Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 11 days ago - Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors - GlobeNewsWire
- 13 days ago - Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting - GlobeNewsWire
- 5 weeks ago - Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program - GlobeNewsWire
- 2 months ago - Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 2 months ago - Marker Therapeutics Stock Drops After Report About Lymphoma Treatment - Benzinga
- 2 months ago - Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma - GlobeNewsWire
- 3 months ago - Marker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference - GlobeNewsWire